Home > Healthcare > Pharmaceuticals > Finished Drug Form > Neuroprotection Market
The global population is aging rapidly, with a significant increase in the proportion of elderly individuals in many countries. Aging is a major risk factor for neurodegenerative diseases and age-related cognitive decline, leading to a higher prevalence of conditions such as Alzheimer's and Parkinson's diseases.
For instance, according to the World Health Organization (WHO), by 2030, one-sixth of the global population will be aged 60 or older, increasing from 1 billion in 2020 to 1.4 billion. By 2050, the number of individuals aged 60 and above is expected to double to 2.1 billion, with the number of those aged 80 or older tripling to 426 million. Thus, as the elderly population grows, there is a corresponding rise in demand for neuroprotection therapies to address age-related neurological disorders and maintain cognitive function in older adults.